양압호흡기 시장 규모, 점유율, 동향 및 예측 : 제품 유형, 최종사용자, 지역별(2026-2034년)

The global positive airway pressure devices market size was valued at USD 4.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.2 Billion by 2034, exhibiting a CAGR of 4.93% from 2026-2034. North America currently dominates the market, holding a market share of 35% in 2025. The region benefits from advanced healthcare infrastructure, well-established reimbursement policies for sleep disorder treatments, high clinical awareness, and strong patient demand for PAP therapy, all collectively contributing to the positive airway pressure devices market share.

The market is driven by a combination of epidemiological, technological, and policy related factors. The increasing global occurrence of obstructive sleep apnea (OSA) driven by the heightened incidence of obesity, sedentary lifestyle habits, and aging populations, is creating a large pool of patient base for positive airway pressure (PAP) therapy. Apart from this, the increasing awareness about the severe health consequences of untreated sleep apnea, like hypertension, diabetes, and depression, is encouraging people to seek timely treatment. Favorable reimbursement policies by the government are lowering economic barriers and facilitating the adoption of effective devices. In addition, the increasing healthcare expenditure in emerging countries is gradually rising access to PAP devices, thereby expanding the global patient base and supporting the positive airway pressure devices market growth.

The United States has become a prominent area in the positive airway pressure devices market because of numerous reasons. The country has an established healthcare system with extensive insurance coverage for PAP therapy, advanced sleep diagnostic facilities, and a high level of awareness among healthcare professionals about sleep disorders. The United States also has strong investments in medical device R&D, which has led to the quick introduction of next-generation PAP devices in the market. One of the most important factors that have contributed to the adoption of positive airway pressure devices is the rising number of obesity-related sleep apnea cases, as stated in a study published in Resmed in 2025, nearly 77 million U.S. adults, which shows a relative increase of almost 35% since 2020 and affects 46% of adults aged 30-69 years. The integration of telehealth with PAP devices has also helped in monitoring therapy sessions and improving patient compliance with treatment regimens in the United States.

POSITIVE AIRWAY PRESSURE DEVICES MARKET TRENDS:

Heightened Awareness about Consequences of Sleep Apnea

The growing international incidence of obstructive sleep apnea represents one of the most influential drivers of demand for PAP therapy. OSA, which is defined by recurrent episodes of breathing cessation during sleep, has been closely linked to obesity, advancing age, and lifestyle factors such as a sedentary lifestyle and alcohol use. As greater numbers of healthcare providers and public health agencies invest in large-scale screening programs and education campaigns, more patients are being diagnosed with OSA and subsequently treated with PAP therapy. Governments in various international regions have placed a high priority on sleep health initiatives, with insurance companies expanding their coverage to include PAP therapy and accessories. The growing recognition of the link between undiagnosed and untreated OSA and chronic diseases such as hypertension, stroke, heart failure, and type 2 diabetes is further fueling the need for diagnosis and treatment. In 2025, SleepRes, Inc. announced that it has received FDA 510(k) clearance for its Kricket PAP system, which employs Kairos Positive Airway Pressure (KPAP) to treat obstructive sleep apnea in patients weighing more than 66 pounds.

Escalating Demand for Home-Based PAP Therapy

The paradigm shift towards home-based healthcare management is, at its core, revolutionizing the positive airway pressure devices market trends and end-users of positive airway pressure devices. Increasing healthcare expenditures, the risk of hospital-acquired infections, and the growing demand for patient-centric care have collectively encouraged more patients to take charge of their sleep apnea treatment in the comfort of their own homes. Contemporary home-use PAP devices are extremely portable, easy to use, and engineered with noise-reduced motors and intuitive interfaces that allow for independent use. The growing availability of home sleep testing services has also made the process more streamlined, allowing patients to quickly begin PAP therapy outside of the sleep lab. Healthcare professionals are increasingly using telemedicine platforms available on PAP devices to track therapy compliance and adjust pressures remotely, minimizing the need for follow-up consultations. In 2025, Happy Health's Happy Ring received FDA approval for home sleep testing, boasting high accuracy rates compared to the gold standard of polysomnography, illustrating the rapidly increasing integration of diagnostic technology and home-based care in this rapidly changing industry.

Technological Advancements Enhancing Device Performance

Innovation in PAP technology is changing the face of treatment for sleep-disordered breathing. The positive airway pressure devices market outlook is being influenced by the need for quieter, more portable devices with advanced features such as automatic pressure adjustment, heated humidifiers, and cloud-based monitoring systems that allow remote tracking of patient compliance by healthcare professionals. These features have been demonstrated to improve patient compliance, which has been a major factor in the effective management of OSA. The development of smart PAP devices with Bluetooth connectivity and mobile apps that enable patients to track therapy information and receive real-time feedback is also personalizing treatment. The use of artificial intelligence algorithms to adjust pressure levels in real-time according to the patient's breathing patterns is also becoming popular in the industry. In 2026, Inogen, Inc., a prominent medical technology firm focused on cutting-edge respiratory products for home care, revealed the introduction of Aurora CPAP masks, a new item in the growing Inogen lineup. Aurora's launch represents an important step in Inogen's strategy to enhance its respiratory care offerings and provide patients with quality, effective masks for obstructive sleep apnea (OSA).

POSITIVE AIRWAY PRESSURE DEVICES INDUSTRY SEGMENTATION:

Analysis by Product Type:

• Automatic Positive Airway Pressure (APAP) Devices
• Continuous Positive Airway Pressure (CPAP) Devices
• Bi-level Positive Airway Pressure (BiPAP) Devices

Continuous positive airway pressure (CPAP) Devices holds 60% of the market share. CPAP devices are the most widely prescribed treatment for obstructive sleep apnea, delivering a continuous, steady stream of pressurized air through a mask to maintain airway patency during sleep. Their clinical effectiveness, cost-efficiency relative to advanced PAP systems, and simplicity of use have firmly established them as the gold standard for OSA management among healthcare providers and patients alike. Ongoing innovation in CPAP technology has further strengthened this dominance, with newer models featuring quieter motors, ergonomic mask designs, auto-adjusting pressure capabilities, and integrated digital health tools that enable remote patient monitoring and compliance tracking. The widespread availability of CPAP devices through home medical equipment providers and online channels has substantially improved accessibility across diverse markets. Strong reimbursement coverage for CPAP devices by government insurance programs in North America and Europe continues to support adoption.

Analysis by End User:

• Hospitals and Sleep Labs
• Home Care
• Others

Hospitals and sleep labs lead the market with a share of 48%. These specialized clinical settings provide comprehensive diagnostic and therapeutic services for patients with sleep-disordered breathing, deploying advanced PAP devices as part of structured treatment protocols under medical supervision. Hospitals are equipped with state-of-the-art sleep laboratories capable of conducting full polysomnography studies, which enable clinicians to accurately titrate PAP pressure settings for individual patients. The presence of multidisciplinary care teams, including pulmonologists, neurologists, and respiratory therapists, ensures high-quality OSA management in hospital environments. Institutional procurement of PAP devices is supported by favorable reimbursement frameworks in key markets, particularly in North America and Europe. Additionally, the integration of hospital-based PAP programs with broader chronic disease management platforms for conditions such as cardiovascular disease and metabolic disorders supports coordinated patient care.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America, accounting for 35% of the share, enjoys the leading position in the market. The region's market leadership is underpinned by high sleep apnea prevalence, advanced healthcare infrastructure, and robust clinical adoption of PAP therapy. The United States has a well-established sleep medicine ecosystem featuring a large network of accredited sleep centers, experienced specialists, and strong insurance reimbursement policies that facilitate patient access to PAP devices. Canada also demonstrates consistent PAP device adoption, driven by government-funded healthcare services and increasing public awareness of sleep disorder management. Moreover, the region benefits from the concentration of leading PAP device manufacturers and an active regulatory environment that facilitates rapid approval and commercialization of innovative products. According to a study published in Respiratory Medicine in September 2025, an estimated 83.7 million adults, representing 32.4% of the United States adult population, had obstructive sleep apnea as of 2024, directly reflecting the robust and growing clinical demand for positive airway pressure devices market forecast-aligned therapeutic interventions across the region.

KEY REGIONAL TAKEAWAYS:

United States Positive Airway Pressure Devices Market Analysis

The United States positive airway pressure devices market is driven by its highly developed healthcare infrastructure, robust sleep medicine specialty ecosystem, and among the highest per-capita rates of sleep apnea diagnosis globally. The widespread availability of accredited sleep diagnostic centers, combined with comprehensive Medicare and private insurance coverage for PAP devices and accessories, significantly reduces the financial burden on patients and encourages timely treatment initiation. Increasing public health campaigns by professional organizations such as the American Academy of Sleep Medicine have substantially elevated awareness of OSA and its associated risks, including cardiovascular disease, stroke, and metabolic disorders. The integration of digital health technologies with PAP devices, including smartphone applications, cloud-based compliance monitoring, and remote patient management platforms, is further improving therapy adherence rates across the US population. Ongoing investment in R&D by domestic manufacturers ensures a steady pipeline of innovative PAP products entering the market. In February, Zydus Lifesciences revealed the introduction of PEPAIR, an Oscillating Positive Expiratory Pressure (OPEP) device aimed at aiding mucus clearance and enhancing breathing in individuals with chronic respiratory disorders, such as chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis.

Europe Positive Airway Pressure Devices Market Analysis

The European positive airway pressure devices market demonstrates consistent growth, supported by universal healthcare systems in major economies including Germany, France, the United Kingdom, Italy, and Spain that provide broad reimbursement coverage for sleep disorder diagnosis and PAP therapy. High awareness levels among healthcare professionals and expanding patient education initiatives have supported increased OSA diagnosis rates across the region. European regulatory bodies maintain rigorous standards for PAP device safety and efficacy, ensuring the availability of high-quality products across regional markets. The aging population in Western Europe, combined with rising obesity rates in younger demographics, continues to expand the pool of at-risk patients requiring PAP therapy. Strong investment in sleep medicine research and clinical trials across European academic institutions is generating evidence that supports guideline-driven PAP prescribing practices. In July 2024, the French government granted reimbursement approval for an innovative neurostimulation-based OSA therapy, reflecting Europe's strong policy commitment to expanding treatment options for sleep disorder patients and underscoring the region's progressive healthcare policy environment.

Asia-Pacific Positive Airway Pressure Devices Market Analysis

The Asia-Pacific positive airway pressure devices market is expanding rapidly, driven by increasing OSA diagnosis rates, growing healthcare expenditure, and improving medical infrastructure across major economies including China, Japan, India, South Korea, and Australia. Rising obesity rates and demographic aging across the region are significantly elevating the burden of sleep-disordered breathing, stimulating demand for PAP therapy. In Japan and South Korea, advanced healthcare infrastructure and strong insurance coverage are supporting high device adoption rates. In China and India, awareness campaigns and the expansion of sleep diagnostic centers are progressively closing the gap between OSA prevalence and diagnosis. As per a report by the Australian Institute of Health and Welfare published in November 2024, the Australian government invested USD 178.7 billion toward healthcare infrastructure development, significantly improving access to diagnostic and therapeutic services, including PAP devices, across the region.

Latin America Positive Airway Pressure Devices Market Analysis

The Latin America positive airway pressure devices market is at an emerging stage but exhibits significant growth potential, driven by increasing awareness of sleep apnea, expanding private healthcare networks, and a rising burden of obesity across the region. Countries including Brazil and Mexico are primary contributors to market activity, supported by improving access to sleep diagnostic services and government-led chronic disease management programs. According to the Pan American Health Organization (PAHO), obesity prevalence among adults in Latin America has increased substantially, with a major section of the adult population classified as obese across several major economies in 2024, directly elevating sleep apnea prevalence and fueling demand for PAP devices.

Middle East and Africa Positive Airway Pressure Devices Market Analysis

The Middle East and Africa positive airway pressure devices market is gradually developing, with significant growth potential concentrated in Gulf Cooperation Council (GCC) states including Saudi Arabia and the United Arab Emirates, where high obesity prevalence and rising healthcare investment are supporting market expansion. Africa's market remains nascent, constrained by limited healthcare infrastructure and low awareness. According to the World Health Organization (WHO), some GCC nations reported adult obesity rates increasing excessively, directly elevating the epidemiological burden of obstructive sleep apnea and increasing demand for PAP therapy. Government-backed healthcare modernization programs across the region are progressively expanding access to sleep diagnostic services and PAP treatment options.

COMPETITIVE LANDSCAPE:

The global positive airway pressure devices market is characterized by intense competition, with established multinational corporations and specialized medical device companies competing through continuous product innovation, regulatory approvals, and strategic collaborations. Leading players are focused on expanding their PAP device portfolios with advanced features including automated pressure adjustment, reduced noise levels, smart connectivity, and integrated cloud-based data platforms to differentiate their offerings and improve patient adherence. Strategic investments in research and development remain a priority as companies seek to address common barriers to long-term therapy compliance, including device discomfort and complexity. Partnerships with telehealth providers, insurance companies, and hospital networks are being pursued to enhance market reach and streamline patient access. While regulatory compliance and post-market surveillance requirements present ongoing operational complexities, leading manufacturers are investing in quality management systems and clinical evidence generation to support commercialization efforts across international markets and sustain their competitive positions.

The report provides a comprehensive analysis of the competitive landscape in the positive airway pressure devices market with detailed profiles of all major companies, including:

• 3B Medical Inc.
• Apex Medical Corp.
• Compumedics Limited (D & DJ Burton Holdings Pty Ltd.)
• Drive Devilbiss Healthcare (Drive International LLC)
• Fisher & Paykel Healthcare Limited
• Koninklijke Philips N.V.
• Resmed Inc.
• Smiths Group Plc
• Somnetics International Inc.
• Vyaire Medical Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the positive airway pressure devices market?

2. What is the future outlook of the positive airway pressure devices market?

3. What are the key factors driving the positive airway pressure devices market?

4. Which region accounts for the largest positive airway pressure devices market share?

5. Which are the leading companies in the global positive airway pressure devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Positive Airway Pressure Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Automatic Positive Airway Pressure (APAP) Devices
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Continuous Positive Airway Pressure (CPAP) Devices
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Bi-level Positive Airway Pressure (BiPAP) Devices
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals and Sleep Labs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Home Care
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 3B Medical Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 Apex Medical Corp.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
  • 13.3.3 Compumedics Limited (D & DJ Burton Holdings Pty Ltd.)
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
  • 13.3.4 Drive Devilbiss Healthcare (Drive International LLC)
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
  • 13.3.5 Fisher & Paykel Healthcare Limited
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Koninklijke Philips N.V.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Resmed Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Smiths Group Plc
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Somnetics International Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 Vyaire Medical Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio